Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × envafolimab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Biliary Tract Neoplasms 4 Sarcoma 3 Advanced or Metastatic Solid Tumors 3 Uterine Cervical Neoplasms 2 Solid Tumors 2 Rectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Stomach Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Rare Tumour 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasms, Multiple Primary 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 NSCLC 1 Meningeal Carcinomatosis 1 Lung Neoplasms 1 Locally Advanced Rectal Carcinoma 1 Histiocytoma, Malignant Fibrous 1 HER2-positive Breast Cancer 1 Gastrointestinal Stromal Tumors 1 Gastrointestinal Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Dermatofibrosarcoma 1

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡